Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAT010 in advanced solid tumors
NCT06277219Phase 2Recruiting
- Sponsor
- Latticon Antibody Therapeutics, Inc.
- Start
- Jun 2024
- Primary completion
- Dec 2026
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of LAT010 in solid tumor, sponsored by Latticon Antibody Therapeutics, Inc.. Started Jun 2024; status: recruiting.
02
Drugs
LAT010
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06277219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277219.